KRAS and non-small cell lung carcinoma: Skoulidis et al. [71] retrospectively assessed 17 KRAS mutant NSCLC treated with nivolumab, showing poorer responses in cases of KRAS/STK11 co-mutation compared to those with KRAS/TP53 co-mutation.